Tao Capital Management’s Faeth Therapeutics FTH Stock Holding History

Tao Capital Management’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,639	Closed	-$345K	–	17
2021 Q3	$345K	Buy	+1,639	New	+$298K	0.09%	14

Other funds holding FTH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Tao Capital Management's FTH Position: Q4 2021 in Review

Tao Capital Management sold out of Faeth Therapeutics (FTH) in Q4 2021, closing a stake of 1,639 shares — an estimated $345K sold.

Tao Capital Management first reported a position in FTH in Q3 2021 and held it in 1 quarter. The position peaked at $345K in Q3 2021. 37 funds tracked by Wall St. Rank hold FTH as of Q4 2021.

Tao Capital Management reported no remaining Faeth Therapeutics position as of Q4 2021 after selling out during the quarter.
Tao Capital Management sold 1,639 Faeth Therapeutics shares in Q4 2021, an estimated $345K.
Tao Capital Management first reported a position in Faeth Therapeutics in Q3 2021 and held it in 1 quarter.
Tao Capital Management's Faeth Therapeutics position peaked at $345K in Q3 2021.
37 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q4 2021.

Based on Tao Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.